At Biomedcode, we perform preclinical development in alignment with our Clients’ needs in order to develop new animal models that meet the Pharmaceutical Industry’s requirements. Recent examples of such activities include the development and standardization of the CAIA model in human TNF transgenic mice (Tg1278TNFko) as well as the development and standardization of the acute TNBS colitis model in human TNF transgenic mice (Tg197).
Biomedcode is a CRO company aiming to develop fully integrated preclinical efficacy evaluation platforms including the integration of molecular data that can improve the significance and reliability of the results and offer insights on the mode of action of the tested therapeutics. Towards this direction, Biomedcode has developed pharmacogenomics, metabonomics and other technological tools to complement existing and future preclinical drug evaluation platforms.
The proper evaluation of novel therapeutics requires the use of well characterized and standardized preclinical disease models. All procedures related to the induction of the disease and/or the evaluation of pathological signs have to be accurate, reproducible and perfectly coordinated to meet the requirements of a specific project.